

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Ocumention Therapeutics**  
**歐康維視生物**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 1477)**

**CHANGE OF JOINT COMPANY SECRETARY,  
AUTHORIZED REPRESENTATIVE AND PROCESS AGENT  
AND  
WAIVER FROM STRICT COMPLIANCE WITH  
RULES 3.28 AND 8.17 OF THE LISTING RULES**

**CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND  
PROCESS AGENT**

The board (the “**Board**”) of directors of Ocumention Therapeutics (the “**Company**”, together with its subsidiaries, the “**Group**”) has been informed that Ms. Pui Chun Hannah SUEN (“**Ms. SUEN**”) who is a joint company secretary of the Company (the “**Joint Company Secretary**”), has tendered her resignation as the manager of corporate services of Vistra Corporate Services (HK) Limited, which is the external corporate services provider of the Company. As a result of the aforesaid resignation, Ms. SUEN ceased to act as (i) the Joint Company Secretary; (ii) an authorized representative of the Company pursuant to Rule 3.05 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Authorized Representative**”); and (iii) an authorized representative of the Company to accept service of process and notices on behalf of the Company in Hong Kong as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from June 15, 2022.

Ms. SUEN has confirmed that she does not have any disagreement with the Board and there are no other matters in relation to her cessation to act in the above positions of the Company that need to be brought to the attention of the shareholders of the Company and the Stock Exchange.

Following the cessation of Ms. SUEN to act as a Joint Company Secretary, the Board is pleased to announce that Ms. CHAU Hing Ling (“**Ms. CHAU**”) has been appointed as a Joint Company Secretary, the Authorized Representative and the Process Agent with effect from June 15, 2022. Ms. Yun JI (“**Ms. JI**”) will continue to serve as the other Joint Company Secretary.

The biographical details of Ms. JI and Ms. CHAU are set out below:

### **Ms. JI**

Ms. JI was appointed as the Secretary of the Board and the Joint Company Secretary on April 28, 2020. Ms. JI has been our strategic project director since February 27, 2020, responsible for our IPO project and the following capitalization operation. Prior to joining our Group, from September 2012 to February 2020, she served as head manager of board of directors office in Shanghai Pharmaceuticals Holding Co., Ltd. (上海醫藥集團股份有限公司), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 601607) and the Stock Exchange (stock code: 2607), where she led a team responsible for corporate governance, public disclosure, investor relations management and other securities affairs.

Ms. JI obtained her bachelor’s degree in business administration from Beijing Foreign Studies University in Beijing, China in July 2007.

### **Ms. CHAU**

Ms. CHAU is currently an executive director of corporate services of Vistra Corporate Services (HK) Limited. She has over twenty years of experience in the corporate services industry. She is currently the company secretary/joint company secretaries of certain listed companies.

Ms. CHAU obtained a master of laws majoring in corporate and financial law from The University of Hong Kong in November 2007. She has been a fellow member of The Hong Kong Chartered Governance Institute and a fellow member of The Chartered Governance Institute in United Kingdom since May 2013.

## **WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

Reference is made to the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Ms. JI to act as a Joint Company Secretary for a three-year period from the date of the Company’s listing on the Main Board of the Stock Exchange (i.e. from July 10, 2020 to July 9, 2023) (the “**Waiver Period**”), on the condition that Ms. JI would be assisted by Ms. SUEN, who possesses the qualifications required under Rule 3.28 of the Listing Rules, during the Waiver Period. Relevant details of the Waiver were disclosed in the section headed “Waivers from Compliance with the Listing Rules and Exemption from the Companies (Winding Up and Miscellaneous Provisions) Ordinance—Joint Company Secretaries” of the prospectus of the Company dated June 29, 2020.

Given the condition of the Waiver could no longer be fulfilled following the departure of Ms. SUEN, the Company has applied to the Stock Exchange and has already been granted with a new waiver (the “**New Waiver**”) by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for the remaining period of the Waiver Period (i.e. from June 15, 2022 to July 9, 2023) (the “**New Waiver Period**”) in relation to the eligibility of Ms. JI to act as a Joint Company Secretary, on the conditions that:–

- (i) Ms. JI must be assisted by Ms. CHAU during the New Waiver Period;
- (ii) the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company; and
- (iii) the Company will announce the reasons for, and the details and conditions of the New Waiver, and the qualification and experience of both Ms. JI and Ms. CHAU.

The publication of this announcement aims to satisfy condition (iii) set out above.

Before the end of the New Waiver Period, the Company must demonstrate and seek the Stock Exchange’s confirmation that Ms. JI, having had the benefit of Ms. CHAU’s assistance during the New Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The New Waiver applied to Ms. CHAU’s appointment as the Joint Company Secretary only. The Stock Exchange may withdraw or change the New Waiver if the Company’s situation changes.

The Board would like to take this opportunity to express its gratitude to Ms. SUEN for her valuable contributions to the Company during her tenure of service and extend its warm welcome to Ms. CHAU on her new appointment.

By order of the Board  
**Ocumension Therapeutics**  
**Dr. Lian Yong CHEN**  
*Chairman and Non-executive Director*

Hong Kong, June 15, 2022

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive directors, Dr. Lian Yong CHEN, Dr. Wei LI, Mr. Yanling CAO and Ms. Yumeng WANG as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive directors.*